Company intelligence / Profile preview
Axter Therapeutics
Beijing, Beijing, Chinaaxtertx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Axter Therapeutics is a China-based biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. Its lead asset, AXT‑1003, is an oral small molecule EZH2 degrader currently in Phase 1 clinical trials for advanced malignancies and lymphomas. The compound was licensed from Novartis. Early-stage results are focused on safety, pharmacokinetics, and preliminary anti-tumor activity; no efficacy data has been published yet.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesTargeted protein degraders
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Novartis – licensing agreement for global development/commercialization rights to AXT‑1003.
Beyond the preview
Go deeper on Axter Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axter Therapeutics.